Re-reading the CEO letter from the Annual Report, I noted for...

Re-reading the CEO letter from the Annual Report, I noted for the first time the significance of the dual approach to commercialisation. We tend to focus on the out-licencing of the platform and ignore the in-licensing of a cargo for PYC to progress independently into the clinic. Where would we get hold of a perfectly good PMO under commercial terms affordable to a small Australian biotech? Big Pharma strike licencing deals with small biotech companies for several hundreds of millions of dollars - that's the end game for Phylogica isn't it? But the other way round - Phylogica in-licencing!

I suspect there are a number of orphan PMOs around looking for a new home. Drugs that have gone through clinical trials with billions-of-dollars invested but which haven't come up trumps for various reasons. More particularly we are interested in PMO drugs which cant get into cells without high dosages and associated toxicity. PMO technology it would seem is a good idea in search of a delivery vehicle.

Now that I think about it, there are a number of examples that come to mind.